SCHEMBL6206868

SCHEMBL6206868

CC(C)(C)OC(=O)CC(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.39
CYP2D6 P10635 1/20 0.38
CA2 P00918 2/20 0.36
CA12 O43570 2/20 0.36
CA14 Q9ULX7 2/20 0.36
TDP1 Q9NUW8 1/20 0.35
KMT2A Q03164 2/20 0.34
CA1 P00915 2/20 0.34
CA7 P43166 2/20 0.34
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
APLNR P35414 1/20 0.32
TSHR P16473 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL241533 0.84 DGAT1 (0.46) DGAT1CYP2D6CA2CA12CA14
Methyl Alcohol SCHEMBL27995686 0.81 DGAT1 (0.44) DGAT1CYP2D6CA2CA12CA14
SCHEMBL9464796 0.81 CA14 (0.38) DGAT1CYP2D6CA2CA12CA14
SCHEMBL19216586 0.81 DGAT1 (0.37) DGAT1CYP2D6CA2CA12CA14
SCHEMBL12203255 0.79 DGAT1 (0.35) DGAT1CYP2D6CA2CA12CA14
SCHEMBL18787715 0.79 DGAT1 (0.40) DGAT1CYP2D6CA2CA12CA14
SCHEMBL204758 0.79 GAA (0.50) DGAT1CA2CA12CA14KMT2A
SCHEMBL28316203 0.79 DGAT1 (0.42) DGAT1CYP2D6CA2CA12CA14
SCHEMBL2648388 0.79 DGAT1 (0.42) DGAT1CYP2D6CA2CA12CA14
SCHEMBL19862462 0.78 STING1 (0.37) DGAT1CYP2D6CA2CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115461147-A Curing catalyst and resin composition 广荣化学株式会社 2022-12-09 CN claimed
JP-2763676-B2 1998-06-11 JP claimed
EP-0376859-B1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1993-03-31 EP claimed
EP-0448602-A1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1991-10-02 EP claimed
US-5051529-A Transesterification, amidation and acetoacetylation of amines, alcohols, mercaptans and polymers EASTMAN KODAK COMPANY (US) 1991-09-24 US claimed
EP-0376859-A1 Method for functionalization of nucleophiles EASTMAN KODAK COMPANY (US) 1990-07-04 EP claimed
WO-1990006911-A1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1990-06-28 WO claimed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF PHARMARON UK LTD. (GB) 2024-05-09 US disclosed
CN-115461147-A Curing catalyst and resin composition 广荣化学株式会社 2022-12-09 CN disclosed
WO-2022159745-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF HIBERCELL, INC. (US) 2022-07-28 WO disclosed
EP-2857427-B1 CATALYST COMPOSITION FOR POLYURETHANE RESIN PRODUCTION AND METHOD FOR PRODUCING POLYURETHANE RESIN USING SAME TOSOH CORP (JP) 2020-01-08 EP disclosed
US-10442808-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors NOVARTIS AG (CH) 2019-10-15 US disclosed
EP-0376859-B1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1993-03-31 EP disclosed
US-5113011-A Acetoacetylation EASTMAN KODAK COMPANY (US) 1992-05-12 US disclosed
EP-0448602-A1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1991-10-02 EP disclosed
US-5051529-A Transesterification, amidation and acetoacetylation of amines, alcohols, mercaptans and polymers EASTMAN KODAK COMPANY (US) 1991-09-24 US disclosed
EP-0418175-A2 Isoxazoles herbicides RHONE POULENC AGRICULTURE LTD. (GB) 1991-03-20 EP disclosed
EP-0376859-A1 Method for functionalization of nucleophiles EASTMAN KODAK COMPANY (US) 1990-07-04 EP disclosed
WO-1990006911-A1 METHOD FOR FUNCTIONALIZATION OF NUCLEOPHILES EASTMAN KODAK COMPANY (US) 1990-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150345-A1 GCN2 MODULATING COMPOUNDS AND USES THEREOF EIF2AK4, GCN1, CLN6 DGAT1 565/4885CYP2D6 4628/4885CA2 4232/4885
US-10442808-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors FBP1, MMEL1, MALT1 DGAT1 4453/4885CYP2D6 315/4885CA2 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.